Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002008 | An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia | PHASE1 | COMPLETED | - | — | — | - | - | Jun 24, 2005 | 2 | United States |
| NCT00002009 | A Phase I/II Study of Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia | PHASE1 | COMPLETED | - | — | — | - | - | Jun 24, 2005 | 2 | United States |
| Name | Type | Description |
|---|---|---|
| Sargramostim | DRUG | - |
Inclusion Criteria Patients must have: * Serum antibody to HIV with or without evidence of HIV. * Antigenemia. * Anticipated survival of at least 6 months. * Allowed: * Kaposi's sarcoma. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: ...